Form 4: Aprea Therapeutics Director John Henneman III Acquires Shares and Stock Options

Director John Henneman III acquired 1,045 shares of common stock and 4,185 stock options in Aprea Therapeutics on June 20, 2024.

Summary

• On June 20, 2024, John Henneman III, a director of Aprea Therapeutics, acquired 1,045 shares of common stock.
• These shares were granted as restricted stock units and will vest on June 20, 2025, contingent upon continued service on the board.
• Henneman also acquired 4,185 stock options with an exercise price of $4.07, vesting fully on June 20, 2025, also contingent on continued board service.
• Following these transactions, Henneman directly owns 9,184 shares of common stock and 4,185 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It reflects standard insider activity, which can be interpreted as a sign of confidence, but it's not a major event.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future.

Risks

• The vesting of the restricted stock units and stock options is contingent upon continued service on the board, which introduces a dependency on Henneman's continued involvement.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting of the shares and options is tied to continued service on the board.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring such transactions can provide insights into management's sentiment about the company's prospects.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of compensation for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant similar equity-based compensation to their board members.
• The vesting schedules and terms are generally in line with industry standards, designed to align the interests of directors with those of shareholders over the long term.

Stakeholder Impact

• The acquisition of shares and stock options by a director can have a minor positive impact on shareholder sentiment.

Key Dates